This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
What's in Store for Canopy Growth (CGC) in Q2 Earnings?
by Zacks Equity Research
In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.
Here's Why Canopy Growth Corporation (CGC) Fell More Than Broader Market
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $0.51, denoting a -1.03% change from the preceding trading day.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and latest launches.
Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties
by Zacks Equity Research
Canopy Growth, Green Thumb Industries, Tilray Brands and Innovative Industrial Properties are part of the Zacks Investment Ideas article.
3 Cannabis Stocks Soaring on HHS' Recommendation to DEA
by Abhinab Dasgupta
Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.
Time to Get High on Pot Stocks? (3 Catalysts)
by Andrew Rocco
When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 60% and 16.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 14.04% and 6.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of -6.78% and 2.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Canopy Growth (CGC) in Q1 Earnings?
by Zacks Equity Research
Strong demand for legal cannabis products in the Canadian recreational cannabis market and the launch of new products are expected to have driven Canopy Growth's (CGC) Q1 performance.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.39, marking a -0.85% move from the previous day.
Canopy Growth (CGC) Improves Liquidity With Another Selloff
by Zacks Equity Research
Canopy Growth's (CGC) decision to divest facilities aligns with its organizational transformation plan.
Rockwell Medical (RMTI) Soars 20.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Rockwell Medical (RMTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -91.67% and 10.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -32.52% in 4 Weeks
by Zacks Equity Research
Canopy Growth Corporation (CGC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -32.59% in 4 Weeks, Here's Why Canopy Growth Corporation (CGC) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Canopy Growth Corporation (CGC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Medtronic (MDT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.64% and 3.59%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Ayr Wellness Inc. (AYRWF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayr Wellness Inc. (AYRWF) delivered earnings and revenue surprises of 71.11% and 5.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 16.67% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 2.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Canopy Growth Corporation (CGC) is Poised for a Turnaround After Losing -23.9% in 4 Weeks
by Zacks Equity Research
Canopy Growth Corporation (CGC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Ideas feature highlights: Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF
by Zacks Equity Research
Canopy Growth, Green Thumb Industries and AdvisorShares Pure US Cannabis ETF have been highlighted in this Investment Ideas article.